MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET 2019-2028

Lifesciences | Pharmaceuticals

MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET 2019-2028

Market by Device Type, Route of Administration, End-user, and Country | Forecast 2019-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

As per Triton's research report, the Middle East and African injectable drug delivery market is anticipated to upsurge with a CAGR of 9.63% in the forecasting years of 2019-2028.



Report scope can be customized per your requirements. Request For Customization

The countries reviewed in this market are:

           Saudi Arabia

           Turkey

           The UAE

           South Africa

           Rest of MEA

TurkStat, the statistical authority of Turkey, states that the country had a geriatric population of 7.2 million in 2018. This has been a solid jump of around 16% from around 6.2 million in 2014. In addition, around 3.4 million adults living in the country were reported to be affected by CVDs in 2016, states the NCBI. The increase in the aged populace, coupled with the increasing prevalence of cardiovascular diseases, is anticipated to drive the Turkish drug delivery market growth.

According to an article published in 2018, Saudi Arabia's geriatric population aged 60 and above will reach 25% of the country’s total population by 2050. Also, the number of people aged 80 and above is predicted to reach 1.6 million, accounting for $4% of the total population in the same time frame. Owing to this rise in the elderly population, healthcare spending in the country is expected to increase significantly in the coming years.

Further, according to another article, the growing prevalence of cardiovascular diseases (CVDs) has become a cause of major public health concern. CVDs are responsible for nearly 46% of the total death rate in the country. Injectable drug delivery technology has emerged as a source of relief for the elderly and CVD patients, as they help provide a better quality of life to them. These factors are fueling the growth of the KSA injectable drug delivery market over the forecast period.

Teva Pharmaceuticals was established in 1901 by Moshe Levin, Yitschak Elstein, and Chaim Salomon. It has a rich experience of more than 115 years in the pharmaceutical industry. In the field of injectable drug delivery solutions, it offers Norepinephrine bitartrate injection (Levophed), Levoleucovorin for injection (Fusilev), Fludarabine phosphate injection, Vecuronium bromide for injection, Sumatriptan Injection Prefilled Syringe, and COPAXONE (prefilled syringe), among others. The company is headquartered in Petah Tikva, Israel.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCES MODEL

2.2.1.   THREAT OF NEW ENTRANT

2.2.2.   THREAT OF SUBSTITUTE

2.2.3.   BARGAINING POWER OF BUYERS

2.2.4.   BARGAINING POWER OF SUPPLIERS

2.2.5.   INTENSITY OF COMPETITIVE RIVALRY

2.3. KEY INSIGHT

2.4. KEY BUYING CRITERIA

2.5. MARKET ATTRACTIVENESS INDEX

2.6. MARKET DRIVERS

2.6.1.   INCREASING GERIATRIC POPULATION

2.6.2.   TECHNOLOGICAL ADVANCEMENT

2.6.3.   GROWING OCCURRENCE OF AUTOIMMUNE DISEASES

2.7. MARKET RESTRAINTS

2.7.1.   HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS

2.8. MARKET OPPORTUNITIES

2.8.1.   DEVELOPMENT OF BETTER INJECTABLE SYSTEMS

2.8.2.   INCREASE IN HEALTHCARE EXPENDITURE

2.9. MARKET CHALLENGES

2.9.1.   DEVELOPMENTS IN THE ALTERNATE DRUG DELIVERY SYSTEMS

2.9.2.   STRINGENT REGULATIONS

3.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE

3.1. PEN INJECTOR

3.2. AUTO-INJECTOR

3.3. NEEDLE-FREE INJECTOR

3.4. PREFILLED SYRINGE

4.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION

4.1. SUBCUTANEOUS

4.2. INTRAMUSCULAR

4.3. INTRAVENOUS (IV)

4.4. OTHER ROUTE OF ADMINISTRATION

5.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER

5.1. CLINICS/ PHYSICIAN OFFICES

5.2. AMBULATORY CARE

5.3. HOSPITAL

5.4. HOME-BASED

5.5. OTHER END-USERS

6.    INJECTABLE DRUG DELIVERY MARKET – MIDDLE EAST AND AFRICA

6.1. COUNTRY ANALYSIS

6.1.1.   SAUDI ARABIA

6.1.2.   TURKEY

6.1.3.   UNITED ARAB EMIRATES

6.1.4.   SOUTH AFRICA

6.1.5.   REST OF MIDDLE EAST & AFRICA

7.    COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC

7.2. BECTON DICKINSON AND COMPANY (BD)

7.3. ELCAM MEDICAL

7.4. ELI LILLY AND COMPANY

7.5. GERRESHEIMER

7.6. INJEX

7.7. NOVARTIS AG

7.8. NOVO NORDISK A/S

7.9. PFIZER INC

7.10. SANOFI SA

7.11.  SCHOTT AG

7.12. TERUMO CORPORATION

7.13.  TEVA PHARMACEUTICALS

7.14.   WEST PHARMACEUTICALS

7.15.   YPSOMED HOLDING AG

8.    RESEARCH METHODOLOGY & SCOPE

8.1. RESEARCH SCOPE & DELIVERABLES

8.1.1.   OBJECTIVES OF STUDY

8.1.2.   SCOPE OF STUDY

8.2. SOURCES OF DATA

8.2.1.   PRIMARY DATA SOURCES

8.2.2.   SECONDARY DATA SOURCES

8.3. RESEARCH METHODOLOGY

8.3.1.   EVALUATION OF PROPOSED MARKET

8.3.2.   IDENTIFICATION OF DATA SOURCES

8.3.3.   ASSESSMENT OF MARKET DETERMINANTS

8.3.4.   DATA COLLECTION

8.3.5.   DATA VALIDATION & ANALYSIS

List of table

TABLE 1        MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)

TABLE 2        MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)

TABLE 3        DIFFERENT TYPES OF INSULIN PEN INJECTORS

TABLE 4        MARKETED NEEDLE-FREE INJECTORS PRODUCTS

TABLE 5        LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE

TABLE 6        MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)

TABLE 7        MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)

TABLE 8        MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)

List of Figures

FIGURE 1      MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE 2      KEY BUYING IMPACT ANALYSIS

FIGURE 3      MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)

FIGURE 4      MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY AUTO-INJECTOR, 2019-2028 ($ MILLION)

FIGURE 5      MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)

FIGURE 6      MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)

FIGURE 7      MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)

FIGURE 8      MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR, 2019-2028 ($ MILLION)

FIGURE 9      MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS, 2019-2028 ($ MILLION)

FIGURE 10   MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)

FIGURE 11   MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/PHYSICIAN OFFICES, 2019-2028 ($ MILLION)

FIGURE 12   MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)

FIGURE 13   MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)

FIGURE 14   MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)

FIGURE 15   MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)

FIGURE 16   SAUDI ARABIA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE 17   TURKEY INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE 18   UNITED ARAB EMIRATES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE 19   SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE 20   REST OF MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;